409 related articles for article (PubMed ID: 33424836)
1. A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens.
Minati R; Perreault C; Thibault P
Front Immunol; 2020; 11():583287. PubMed ID: 33424836
[TBL] [Abstract][Full Text] [Related]
2. Noncoding regions are the main source of targetable tumor-specific antigens.
Laumont CM; Vincent K; Hesnard L; Audemard É; Bonneil É; Laverdure JP; Gendron P; Courcelles M; Hardy MP; Côté C; Durette C; St-Pierre C; Benhammadi M; Lanoix J; Vobecky S; Haddad E; Lemieux S; Thibault P; Perreault C
Sci Transl Med; 2018 Dec; 10(470):. PubMed ID: 30518613
[TBL] [Abstract][Full Text] [Related]
3. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes.
Ehx G; Larouche JD; Durette C; Laverdure JP; Hesnard L; Vincent K; Hardy MP; Thériault C; Rulleau C; Lanoix J; Bonneil E; Feghaly A; Apavaloaei A; Noronha N; Laumont CM; Delisle JS; Vago L; Hébert J; Sauvageau G; Lemieux S; Thibault P; Perreault C
Immunity; 2021 Apr; 54(4):737-752.e10. PubMed ID: 33740418
[TBL] [Abstract][Full Text] [Related]
4. Alternative tumour-specific antigens.
Smith CC; Selitsky SR; Chai S; Armistead PM; Vincent BG; Serody JS
Nat Rev Cancer; 2019 Aug; 19(8):465-478. PubMed ID: 31278396
[TBL] [Abstract][Full Text] [Related]
5. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
6. Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer.
Zhao Q; Laverdure JP; Lanoix J; Durette C; Côté C; Bonneil É; Laumont CM; Gendron P; Vincent K; Courcelles M; Lemieux S; Millar DG; Ohashi PS; Thibault P; Perreault C
Cancer Immunol Res; 2020 Apr; 8(4):544-555. PubMed ID: 32047025
[TBL] [Abstract][Full Text] [Related]
7. Personalized T cell-mediated cancer immunotherapy: progress and challenges.
Bethune MT; Joglekar AV
Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274
[TBL] [Abstract][Full Text] [Related]
8. BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens.
Cuevas MVR; Hardy MP; Larouche JD; Apavaloaei A; Kina E; Vincent K; Gendron P; Laverdure JP; Durette C; Thibault P; Lemieux S; Perreault C; Ehx G
Genome Biol; 2023 Aug; 24(1):188. PubMed ID: 37582761
[TBL] [Abstract][Full Text] [Related]
9. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
10. Proteogenomics: advances in cancer antigen research.
Kanaseki T; Torigoe T
Immunol Med; 2019 Jun; 42(2):65-70. PubMed ID: 31318319
[TBL] [Abstract][Full Text] [Related]
11. Genome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition.
Jia J; Cui J; Liu X; Han J; Yang S; Wei Y; Chen Y
Mol Immunol; 2009 May; 46(8-9):1824-9. PubMed ID: 19243822
[TBL] [Abstract][Full Text] [Related]
12. Neoantigen: A New Breakthrough in Tumor Immunotherapy.
Zhang Z; Lu M; Qin Y; Gao W; Tao L; Su W; Zhong J
Front Immunol; 2021; 12():672356. PubMed ID: 33936118
[TBL] [Abstract][Full Text] [Related]
13. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
[TBL] [Abstract][Full Text] [Related]
14. The Roles of Alternative Splicing in Tumor-immune Cell Interactions.
Wang Y; Zhang H; Jiao B; Nie J; Li X; Wang W; Wang H
Curr Cancer Drug Targets; 2020; 20(10):729-740. PubMed ID: 32560607
[TBL] [Abstract][Full Text] [Related]
15. Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors.
Rivero-Hinojosa S; Grant M; Panigrahi A; Zhang H; Caisova V; Bollard CM; Rood BR
Nat Commun; 2021 Nov; 12(1):6689. PubMed ID: 34795224
[TBL] [Abstract][Full Text] [Related]
16. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy.
Minegishi Y; Haga Y; Ueda K
Cancer Sci; 2024 Apr; 115(4):1048-1059. PubMed ID: 38382459
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy targeting neoantigens.
Lu YC; Robbins PF
Semin Immunol; 2016 Feb; 28(1):22-7. PubMed ID: 26653770
[TBL] [Abstract][Full Text] [Related]
18. Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.
Fritsche J; Rakitsch B; Hoffgaard F; Römer M; Schuster H; Kowalewski DJ; Priemer M; Stos-Zweifel V; Hörzer H; Satelli A; Sonntag A; Goldfinger V; Song C; Mahr A; Ott M; Schoor O; Weinschenk T
Proteomics; 2018 Jun; 18(12):e1700284. PubMed ID: 29505699
[TBL] [Abstract][Full Text] [Related]
19. Proteogenomic discovery of cancer antigens: Neoantigens and beyond.
Kanaseki T; Tokita S; Torigoe T
Pathol Int; 2019 Sep; 69(9):511-518. PubMed ID: 31397525
[TBL] [Abstract][Full Text] [Related]
20. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
Marijt KA; Doorduijn EM; van Hall T
Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
